ライフサイエンスコーパス: peptide receptor

1 f neurons that express the gastrin-releasing peptide receptor.

2 llowing recombination with an affinity clamp peptide receptor.

3 pTatC and Hcf106 is the twin arginine signal peptide receptor.

4 vestigation of nonpeptidyl ligand binding to peptide receptors.

5 or antagonist that targets gastrin-releasing peptide receptors.

6 the kappa opioid and nociceptin/orphanin FQ peptide receptors.

7 FPR1 and FPR2 as sensitive and broad signal peptide receptors.

8 Our results demonstrate that formyl peptide receptor 1 (FPR1) and neutrophilic NADPH oxidase

9 , which then induces TRMP2 binding to formyl peptide receptor 1 (FPR1) and subsequent FPR1 internaliz

10 Binding of formyl peptide receptor 1 (FPR1) by N-formyl peptides can activ

11 Formyl peptide receptor 1 (FPR1) is a G protein-coupled chemoat

12 to be described on human neutrophils, formyl peptide receptor 1 (FPR1), is one such receptor that pla

13 CXC chemokine receptor 2 (CXCR2) and formyl peptide receptor 1 (FPR1), respectively.

14 blocked the osmotic induction of natriuretic peptide receptor 1 (Npr1) gene expression.

15 he G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), little is known about the mo

16 couples the relaxin receptor, relaxin family peptide receptor 1 (RXFP1), to cAMP following receptor s

17 utic benefits of relaxin/insulin-like family peptide receptor 1 activation.

18 series of human relaxin/insulin-like family peptide receptor 1 agonists.

19 c 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).

20 m wild-type mice and mice lacking the formyl peptide receptor 1, we demonstrate that LTB(4) acts as a

21 In these studies, we performed formyl peptide receptor-1 (FPR) localization and evaluated its

22 eriments to study the capacity of the formyl peptide receptor-1 (FPR1) to desensitize chemokine recep

23 (HMGB1), respectively, as well as to formyl peptide receptor-1 (FPR1), which interacts with Annexin

24 tive properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been shown to increas

25 coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)).

26 phonuclear neutrophils (PMNs) through formyl peptide receptor-1 and Toll-like receptor (TLR) 9, respe

27 upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (chromosome 13, rs60249166, o

28 Activation of the G-protein coupled formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lip

29 Formyl peptide receptor 2 (FPR2) emerges as a central receptor

30 Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor

31 Neutrophils expressing formyl peptide receptor 2 (FPR2) play key roles in host defense

32 Selective agonists and antagonists of formyl peptide receptor 2 (Fpr2) suggested that Fpr2 mediated t

33 ion of a peptidomimetic antagonist of formyl peptide receptor 2 (FPR2) was explored by an approach in

34 Formyl peptide receptor 2 (FPR2), a classical chemoattractant r

35 Here we report that formyl peptide receptor 2 (Fpr2/3) null mice display a major ph

36 d activation of the human and mouse N-formyl peptide receptor 2 (huFPR2).

37 st via the natriuretic peptide C/natriuretic peptide receptor 2 (NPPC/NPR2) system, and possibly also

38 e transmembrane guanylyl cyclase natriuretic peptide receptor 2 (NPR2) in response to the agonist C-t

39 s receptor, the guanylyl cyclase natriuretic peptide receptor 2 (Npr2), and the cGMP-dependent kinase

40 produced by the guanylyl cyclase natriuretic peptide receptor 2 (NPR2).

41 interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

42 INSL3 receptor, relaxin/insulin-like family peptide receptor 2 (RXFP2).

43 ations in the gene for vasoactive intestinal peptide receptor 2 (VIPR2), and exonic duplications in C

44 ulation, a GPCR called vasoactive intestinal peptide receptor 2 (VPAC2) is shed, rather than being in

45 Vasoactive intestinal peptide receptor 2 can elicit immune transformation in a

46 Cs isolated from relaxin/insulin-like family peptide receptor 2 gene (Rxfp2) knockout and wild-type m

47 SAnxA1 bound and activated formyl peptide receptor 2 in a similar way as the parental prot

48 othelial-bound cathelicidin activates formyl-peptide receptor 2 on classical monocytes, resulting in

49 sphatidylserine on the dying cell and formyl peptide receptor 2 on the phagocytosing microglia.

50 via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-coupled cleara

51 tion of ALX/FPR2 (lipoxin A4 receptor/formyl peptide receptor 2) expression.

52 2 (FPR2/ALX) and in mFPR2(-/-) (mouse formyl peptide receptor 2) mice lacking the mouse homolog of hu

53 rway epithelial cells in an ALX/FPR2 (formyl peptide receptor 2) receptor-dependent manner.

54 riuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid recept

55 , namely protein phosphatase 5 (PP5), formyl peptide receptor 2, and annexin 1.

56 sulin-like 3 and relaxin/insulin-like family peptide receptor 2, in cases of nonsyndromic cryptorchid

57 We investigated airway levels of formyl peptide receptor 2-lipoxin receptor (FPR2/ALXR), LXA4, a

58 n by experiments with DCs lacking the formyl peptide receptor 2.

59 Here we tested whether the formyl-peptide receptor 2/3 (Fpr2/3)--ortholog to human FPR2/AL

60 ested whether the lipoxin A4 receptor formyl-peptide receptor 2/3 (Fpr2/3; ortholog to human FPR2/lip

61 ecific binding to the AnxA1 receptor (formyl peptide receptor 2/Lipoxin A4 receptor [FPR2/ALX]; IC50

62 LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cys

63 -4 receptor, the Smoothened receptor, formyl peptide receptor-2 (FPR2), the relaxin receptor (LGR7),

64 rfering RNA-induced knockdown of LXA4 formyl peptide receptor-2 (FPR2/ALX) and in mFPR2(-/-) (mouse f

65 Formyl peptide receptor 3 (Fpr3, also known as Fpr-rs1) is a G

66 coupled clearance receptor NPR3 (natriuretic peptide receptor 3).

67 The primary role of natriuretic peptide receptor-3 (NPR3) or NPR-C is in the clearance o

68 concentration by binding to its natriuretic peptide receptor A (NPRA) receptor and, in turn, by acti

69 trial natriuretic peptide (ANP), natriuretic peptide receptor A (NPRA), is expressed in cancer cells,

70 nylyl cyclase 1 (RetGC1) but not natriuretic peptide receptor A (NPRA).

71 The intracellular segment of a natriuretic peptide receptor A guanylyl cyclase failed to bind GCAPs

72 iac fibroblasts known to express natriuretic peptide receptor A.

73 de WKYMVm, a selective agonist of the formyl peptide receptor, a 2-fold increase in leukocyte emigrat

74 e (ANP) binds guanylyl cyclase-A/natriuretic peptide receptor-A (GC-A/NPRA) and produces the intracel

75 delineate the mechanisms of GC-A/natriuretic peptide receptor-A (GC-A/NPRA) gene (Npr1) expression in

76 ptides activate guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA), which plays a critical r

77 epithelial cells resulted in specific formyl peptide receptor activation.

78 Peptide receptor affinities were seen to be as low as 50

79 ate requirements for these specific N-formyl peptide receptor agonists.

80 e of the inside-out signaling through formyl peptide receptor and CXCR4 in the regulation of alpha(4)

81 The plant RLK FERONIA is a peptide receptor and has been implicated in plant growth

82 The prolactin-releasing peptide receptor and its bioactive RF-amide peptide (PrR

83 ymerization to prevent exocytosis via formyl peptide receptor and Rho kinase signaling pathways.

84 s with output being modulated by presynaptic peptide receptors and postsynaptic potassium channels.

85 bility of fsANP to interact with natriuretic peptide receptors and to be proteolytically degraded.

86 ect of olcegepant, a calcitonin gene-related peptide receptor antagonist (1 mg/kg, intravenously), on

87 P-1 secretion was inhibited by both a formyl peptide receptor antagonist and pertussis toxin, suggest

88 en demonstrated that calcitonin gene-related peptide receptor antagonists act in the central nervous

89 Calcitonin gene-related peptide receptor antagonists are effective acute migrain

90 t on the efficacy of calcitonin gene-related peptide receptor antagonists at the level of third-order

91 e central effects of calcitonin gene-related peptide receptor antagonists extend beyond the trigemino

92 r approaches include calcitonin gene-related peptide receptor antagonists.

93 obably the first of a long list, as multiple peptide receptors are now recognized as potential target

94 cyclase B (GC-B), also known as natriuretic peptide receptor B or NPR2, stimulates long bone growth,

95 r-targeted agents, such as gastrin-releasing peptide receptor (BB2r)-targeted peptides, have been inv

96 es neuropeptides in endosomes to disrupt the peptide/receptor/beta-arrestin complex, freeing internal

97 trial myocytes from wild-type or natriuretic peptide receptor C knockout (NPR-C(-/-)) mice.

98 Moreover, we identified natriuretic peptide receptor-C (NPR-C) as the cognate receptor that

99 ds guanylyl cyclase-A (GC-A) and natriuretic peptide receptor-C (NPR-C).

100 The capa peptide receptor, capaR (CG14575), is a G-protein couple

101 rtner, c-Fos, and therefore designed a c-Fos peptide receptor chemically modified to incorporate a th

102 ding a complete conformational model for the peptide-receptor complex.

103 and ECL3, which can orient and stabilize the peptide-receptor complex.

104 N-formyl peptide receptors comprise a group of Gi-coupled recepto

105 crine system by combinations of synaptic and peptide-receptor connections.

106 complexes were assembled using three formyl peptide receptor constructs (wild type, formyl peptide r

107 ctivated protein kinase pathway in an formyl peptide receptor-dependent manner, delineating a mechani

108 , but not nonclassical monocytes in a formyl-peptide receptor-dependent manner.

109 rmation that might play an important role in peptide-receptor docking and further biological behavior

110 revious studies showed that the delta-opioid peptide receptor (DOP-R) is dynamically regulated by exp

111 yl cyclase-A (GC-A) signaling, a natriuretic peptide receptor, exerts renoprotective effects by stimu

112 eceptor, an orthologue of the Drosophila sex peptide receptor, expressed in neighboring apical organ

113 ese effects, whereas recognition by N-formyl peptide receptor family members was dispensable.

114 esin analogs to target the gastrin-releasing peptide receptor for the diagnosis and potential therapy

115 dy that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migrain

116 natants and a potent agonist at human formyl peptide receptor (FPR) 1.

117 xert their function by binding to the formyl peptide receptor (FPR) 2.

118 s, suggesting that this peptide binds formyl peptide receptor (FPR) 2.

119 ogenous anti-inflammatory circuit via formyl peptide receptor (FPR) 2/lipoxin receptor (ALX) (Fpr2/3

120 ions of two separate receptors, the N-formyl peptide receptor (FPR) and the high-affinity IgE recepto

121 ystemic administration of Boc2, a formylated peptide receptor (fpr) antagonist, abrogated the peptide

122 The formyl peptide receptor (Fpr) family is well known for its cont

123 ein-coupled receptor belonging to the formyl peptide receptor (FPR) family, conveys the biological fu

124 Ac2-26 occurred via receptors of the formyl-peptide receptor (FPR) family, most likely FPR-rs2, as d

125 tors comprising 5 of 7 members of the formyl peptide receptor (FPR) family.

126 cFLFLFK-PEG-(64)Cu, that targets the formyl peptide receptor (FPR) on leukocytes is described.

127 The formyl peptide receptor (FPR) on neutrophils, which binds to fo

128 ophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation.

129 he specific role of the high affinity formyl peptide receptor (FPR) was then tested using specific ph

130 The N-formyl peptide receptor (FPR), a G protein-coupled receptor tha

131 his mechanism in the context of the N-formyl peptide receptor (FPR), a well-characterized member of t

132 Human formyl peptide receptor (FPR)-like 1 (FPRL1) and its mouse homo

133 Our investigation of formyl peptide receptor (FPR)-mediated chemotaxis reveals that

134 iated signaling events that couple to formyl peptide receptor (FPR)1 mRNA stabilization, macrophages

135 nduces calcium and chemotaxis through formyl peptide receptor (FPR)2/ALX, whereas its D-stereoisomer

136 one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist.

137 Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1).

138 canonical GRK that phosphorylated the formyl peptide receptor FPR1 and facilitated neutrophil migrati

139 N-formyl peptide receptor (FPR1) and N-formyl peptide receptor-li

140 casts depends on the high-affinity N-formyl peptide receptor, Fpr1.

141 The neutrophil formyl peptide receptors, FPR1 and FPR2, play critical roles fo

142 15-epi-LXA4 activated formyl peptide receptor (FPR2) and GPR120 on alternative macrop

143 The N-formyl peptide receptors (FPRs) are a family of G-protein coupl

144 N-formyl peptide receptors (FPRs) are critical regulators of host

145 N-Formyl peptide receptors (FPRs) are G protein-coupled receptors

146 Formyl peptide receptors (FPRs) are G-protein-coupled receptors

147 eference to the potential role of the formyl peptide receptors (FPRs), a family of G-protein-coupled

148 ion of neuronal specificity by immune formyl peptide receptors (Fprs).

149 pathway activity via interaction with formyl peptide receptors (FPRs).

150 mRNAs for annexin A1 (AnxA1) and the formyl peptide receptors [(Fprs) 1, 2, and 3], a loss of lipid

151 osmoregulatory functions in brain, where SCT peptide/receptor function is required for ANGII action,

152 ptide receptor constructs (wild type, formyl peptide receptor-Galpha(i2) fusion, and formyl peptide r

153 obases upstream of the vasoactive intestinal peptide receptor gene VIPR2.

154 ICK1 interaction partner prolactin-releasing peptide receptor (GPR10).

155 ptide receptor-Galpha(i2) fusion, and formyl peptide receptor-green fluorescent protein fusion) and t

156 sing the G-protein-coupled gastrin-releasing peptide receptor (GRP-R) and is currently in phase I cli

157 radioligands targeting the gastrin-releasing peptide receptor (GRP-R) might offer a specific method f

158 the limited expression of gastrin-releasing peptide receptor (GRPR) and integrin alpha(v)beta(3) as

159 ntly introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist (68)Ga-SB3 ((68)Ga-DO

160 state cancer, radiolabeled gastrin-releasing peptide receptor (GRPr) antagonists have yielded promisi

161 conjugate affinity for the gastrin releasing peptide receptor (GRPR) as determined against [(125)I-Ty

162 ause overexpression of the gastrin-releasing peptide receptor (GRPR) has been reported on various can

163 MOR1D heterodimerizes with gastrin-releasing peptide receptor (GRPR) in the spinal cord, relaying itc

164 The overexpression of gastrin-releasing peptide receptor (GRPR) in various tumor types suggests

165 vious study suggested that gastrin-releasing peptide receptor (GRPR) is an itch-specific gene in the

166 The gastrin-releasing peptide receptor (GRPR) is found to be overexpressed in

167 Gastrin-releasing peptide receptor (GRPR) is overexpressed in human prosta

168 The gastrin-releasing peptide receptor (GRPR) is overexpressed in human prosta

169 The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate can

170 of evidence suggests that gastrin-releasing peptide receptor (GRPR) might be a valuable target in br

171 Ablation of gastrin-releasing peptide receptor (GRPR) or GRPR neurons in the SCN aboli

172 Here we describe that the gastrin-releasing peptide receptor (GRPR) plays an important part in media

173 ation, depends on CGRP and gastrin-releasing peptide receptor (GRPR) transmission because pharmacolog

174 and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)).

175 Gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupl

176 with high affinity for the gastrin-releasing peptide receptor (GRPr), a receptor that is overexpresse

177 Its receptor, gastrin-releasing peptide receptor (GRPR), is expressed by various cell ty

178 their affinity toward the gastrin releasing peptide receptor (GRPr), metabolic stability in blood pl

179 Because expression of the gastrin-releasing peptide receptor (GRPR), somatostatin receptor 2 (SSTR2)

180 with high affinity to the gastrin-releasing peptide receptor (GRPR), which is overexpressed on a var

181 r diagnosis and therapy of gastrin releasing peptide receptor (GRPR)-expressing tumors.

182 or antagonist that targets gastrin-releasing peptide receptor (GRPr).

183 ivity and affinity for the gastrin-releasing peptide receptor (GRPr).

184 Gastrin-releasing peptide receptors (GRPrs) are overexpressed on a variety

185 Gastrin-releasing peptide receptors (GRPRs) expressed on human tumors can

186 uene (TNT) and dinitrotoluene (DNT) targets, peptide receptors have previously been identified with s

187 at contain caveolin proteins and natriuretic peptide receptors, have been implicated in cardiac hyper

188 These include the human formyl peptide receptor, human trace amine-associated receptor,

189 Radiolabeled antagonists of specific peptide receptors identify a higher number of receptor b

190 nstrating the potential of gastrin-releasing-peptide receptor imaging.

191 presented evidence for a role of the formyl peptide receptor in vivo.

192 the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.

193 was not due to a diminished number of formyl peptide receptors in either murine or human PMNs, as mea

194 tified the expression of functional N-formyl peptide receptors in model SK-CO15 intestinal epithelial

195 esence of functional calcitonin gene-related peptide receptors in the ventroposteromedial thalamic nu

196 Stimulation of formyl peptide receptors increases the mitochondrial membrane p

197 TP production and requires an initial formyl peptide receptor-induced Ca(2+) signal that triggers mit

198 ch as naproxen and a calcitonin gene-related peptide receptor inhibitor, olcegepant, were less effect

199 re previously reported to function as formyl peptide receptor inhibitors.

200 A direct peptide-receptor interaction is supported by specific bi

201 novel insights into the oxytocin/vasopressin peptide-receptor interaction, which led to the identific

202 lation has only minor effects on natriuretic peptide receptor interactions but markedly modifies pept

203 For testing high-affinity peptide-receptor interactions in the plasma membrane of

204 ool for the validation and quantification of peptide-receptor interactions in their natural cellular

205 egions may not give a complete reflection of peptide/receptor interactions and should be combined wit

206 dditional experimental constraints to reveal peptide/receptor interactions occurring in the dynamic,

207 It is applicable to other peptide-receptor interfaces and should yield insights ab

208 periodontitis to study Fc receptors, formyl peptide receptor, Interleukin-6, tumor necrosis factor-a

209 igand binding does not stimulate natriuretic peptide receptor internalization and that cellular envir

210 known carbohydrate receptor, designated as I-peptide receptor (IPR), responsible for lung colonizatio

211 Cell-cell communication mediated by secreted peptides, receptor kinases, and downstream mitogen-activ

212 Four arginine-containing peptide receptor ligands (angiotensin II, neurotensin(8-

213 state-specific membrane or gastrin-releasing peptide receptor ligands for the imaging of prostate can

214 of cathelicidin are mediated through formyl peptide receptor-like 1 (FPRL1), we hypothesize that CSA

215 -formyl peptide receptor (FPR1) and N-formyl peptide receptor-like 1 (FPRL1, now known as FPR2) are G

216 volving a G protein-coupled receptor (formyl peptide receptor-like 1 in migration) and the epidermal

217 4, an antagonist of the transmembrane formyl peptide receptor-like 1 protein attenuated LL-37's abili

218 lls occurs via recently characterized formyl peptide receptors located in the plasma membrane.

219 ule formation, suggesting that CRA2 is a CEP peptide receptor mediating both organogenesis programs.

220 nd 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, also known as ORL-1) was discover

221 -agonist to a partial agonist of natriuretic peptide receptor (NPR)-A while maintaining the ability t

222 did not differentially modulate natriuretic peptide receptor (NPR)-A/B activity with respect to T223

223 creased expression of the type A natriuretic peptide receptor (NPR-A), and dehydration natriuresis.

224 nd CNP) can selectively activate natriuretic peptide receptors, NPR-A and NPR-B, raising the cyclic G

225 and the guanylate cyclase-linked natriuretic peptide receptors Npr1 and Npr2 are functionally redunda

226 iculate guanylate cyclase-linked natriuretic peptide receptors Npr1 and Npr2, and activation of prote

227 bilizing G protein-coupled receptors (formyl peptide receptor, P2Y2 purinergic receptor, and calcium-

228 We experimentally analyzed one peptide-receptor pair and found that a neuropeptide can

229 Analysis of peptide-receptor pairs in spatially mapped single-cell t

230 using cAMP activation of the PTH/PTH-related peptide receptor (PPR) as a readout failed to provide an

231 prgQ conjugation operon is controlled by the peptide receptor protein PrgX; binding of the pheromone

232 maging may be used to monitor the effects of peptide receptor radiolabeled targeted therapy in patien

233 has been identified as a possible target for peptide receptor radionuclide imaging and therapy.

234 ion due to (68)Ga-DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4

235 reatic neuroendocrine tumors (GEP NET) after peptide receptor radionuclide therapy (PRRT) are still l

236 Peptide receptor radionuclide therapy (PRRT) has become

237 ty after internal radiation exposure through peptide receptor radionuclide therapy (PRRT) has not yet

238 Peptide receptor radionuclide therapy (PRRT) is a promis

239 Peptide receptor radionuclide therapy (PRRT) may induce

240 types and are, thus, a potential target for peptide receptor radionuclide therapy (PRRT) of cancer.

241 iation with (177)Lu-DOTA-octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) of neuroend

242 crucial for individualized treatment during peptide receptor radionuclide therapy (PRRT).

243 ression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT).

244 in analogs may lead to nephrotoxicity during peptide receptor radionuclide therapy (PRRT).

245 rts of kidney toxicity associated with early peptide receptor radionuclide therapy and (166)Ho-phosph

246 Peptide receptor scintigraphy and peptide receptor radionuclide therapy are successfully a

247 s might further improve the safety window of peptide receptor radionuclide therapy by reducing the li

248 I and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic

249 Peptide receptor radionuclide therapy is a treatment for

250 ostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine

251 ht enhance peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine

252 Dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTA

253 uroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled

254 Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled

255 Peptide receptor radionuclide therapy with (90)Y-DOTATOC

256 In peptide receptor radionuclide therapy with (90)Y-labeled

257 ment in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled

258 However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agen

259 systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemo

260 Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine

261 tients who will qualify for and benefit from peptide receptor radionuclide therapy.

262 well-known target for molecular imaging and peptide receptor radionuclide therapy.

263 easible and may have a significant impact on peptide receptor radionuclide therapy.

264 herapy for differentiated thyroid cancer and peptide receptor radionuclide therapy.

265 P = 0.002), and type of therapy (medical vs. peptide receptor radionuclide therapy: 16.0 vs. 26.0 mo;

266 d management of PETs including discussion of peptide-receptor radionuclide therapy and other novel an

267 quency of false-positive recommendations for peptide-receptor radionuclide therapy occurred in observ

268 , image-based recommendations for or against peptide-receptor radionuclide therapy require experience

269 Interpretations of appropriateness for peptide-receptor radionuclide therapy varied more signif

270 E PET/CT correctly identified 3 patients for peptide-receptor radiotherapy incorrectly classified by

271 The peptide-receptor relationships determine the specificiti

272 heart failure, activates the relaxin family peptide receptor (RXFP1), which is a class A G-protein-c

273 he highly conserved family of relaxin family peptide receptors (RXFPs), mediates the checkpoint funct

274 most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radio

275 Peptide receptor scintigraphy and peptide receptor radio

276 SSTR antagonists such as JR11 might enhance peptide receptor scintigraphy and peptide receptor radio

277 Peptide receptor scintigraphy and peptide receptor radio

278 Here, we demonstrate that the sex peptide receptor (SPR) of Drosophila, known for its role

279 are, respectively, sex peptide (SP) and sex peptide receptor (SPR), the only pair of physically inte

280 and p38 MAPK signaling in response to formyl peptide receptor stimulation.

281 and cAMP accumulation in response to formyl peptide receptor stimulation.

282 co-staining for the calcitonin gene-related peptide receptor subunits calcitonin receptor-like recep

283 cyclase-linked but not clearance natriuretic peptide receptors, supporting designer natriuretic pepti

284 urther reveal a feedback circuit between the peptide-receptor system and auxin response as a mechanis

285 The underlying biology of these peptide/receptor systems, their physiologic and patholog

286 determine whether it is suitable for use in peptide receptor-targeted radionuclide therapy.

287 ), who were subsequently deemed suitable for peptide receptor-targeted therapy.

288 human cancers, providing the opportunity for peptide receptor targeting via radiolabeled bombesin-bas

289 ents of a functional calcitonin gene-related peptide receptor, the calcitonin receptor-like receptor

290 A new family of peptide receptors, the incretin receptor family, overexp

291 n in management, in terms of suitability for peptide receptor therapy, somatostatin analogs, and surg

292 ceptors, such as the calcitonin gene-related peptide receptor, to the plasma membrane.

293 ells stably expressing the gastrin-releasing peptide receptor treated with either phorbol 12-myristat

294 Formyl-peptide receptor type 2 (FPR2), also called ALX (the lip

295 Formyl-peptide receptor type 2 (FPR2; also called ALX because i

296 2, consistent with the idea that natriuretic peptide receptor type 2 (NPR2) signaling inhibits the ac

297 ratio of the signaling receptor, natriuretic peptide receptor type A, to the clearance receptor, nprc

298 ology for predicting binding scores of small peptide receptors vs. volatile compounds is proposed.

299 and an antagonist for the gastrin-releasing peptide receptor were found to have excellent tumor-targ

300 stably expressing the type 1 PTH/PTH-related peptide receptor, whereas the response remained maximal